Applies to Employer plans.
Depends on your plan's benefitCovered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans
Qualification pathways
You can qualify through any one of these.
Weight Loss - Continuation/Already on therapy
All of:
- Patient is 18 years of age or older
- Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose
- Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
- Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
- Patient will NOT be using the requested agent in combination with another targeted weight loss agent
- Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition
Weight Loss - New to therapy with BMI ≥ 30
All of:
- Patient is 18 years of age or older
- Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
- Patient has a baseline BMI ≥ 30 kg/m2
- Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
- Patient will NOT be using the requested agent in combination with another targeted weight loss agent
- Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition
Weight Loss - New to therapy with BMI ≥ 27 and comorbidity
All of:
- Patient is 18 years of age or older
- Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
- Patient has a baseline BMI ≥ 27 kg/m2
- Patient has at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, or cardiovascular disease)
- Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
- Patient will NOT be using the requested agent in combination with another targeted weight loss agent
- Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition
Documentation to bring
- Chart notes or medical record documentation of Body Mass Index (BMI)
- Chart notes or medical record documentation of weight-related comorbid condition, if applicable
- Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)
Quantity limits
- All strengths — 4 pens
Approval and renewal
- Initial approval: 6 months
- Renewal: every 12 months
- Renewal: Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose.
- Renewal: At least 12 weeks on therapy before the first renewal.
Not covered when
- Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1/GIP-GLP-1 approved for T2DM)
- Combination use with another targeted weight loss agent
- Plans without specific benefit language allowing weight loss drug coverage
Policy note: The Zepbound weight loss and OSA indications are covered under a single section IX. The BMI ≥ 27 with comorbidity pathway for weight loss lists cardiovascular disease as an accepted comorbidity (in addition to hypertension and dyslipidemia), which differs slightly from Wegovy's weight loss pathway. Members receiving medication via samples or manufacturer patient assistance programs must meet initial approval criteria.
Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs For Weight Loss Management · View policy document (PDF)